Clinical Evidence for PT-141 The RECONNECT Phase III trials, two identical randomized controlled studies, enrolled 1,247 premenopausal women with HSDD over 24 weeks
Supported by cardiovascular outcome studies, GLP-1-RAs and SGLT2 inhibitors are preferred for patients with DM and CVD [13, 17]
Morgan Healthcare Conference, CEO Mick Farrell said the companys first AI-enabled medical device, Smart Comfort, will help improve both short- and long-term compliance with therapy
(MOV 26789 kb) Morphological conversion of honeycomb into phagocytotic jellyfish microglia (download MOV The representative time lapse was captured in a CX3CR1 mouse beginning 5 hrs following compression injury
For instance, Health Canada has prohibited the sale of supplements containing kava, a plant native to the Pacific islands, due to risk of liver dysfunction
Astellas Pharma US, Inc